Items where authors include "Dodwell, D."

Article

Steventon, L., Nicum, S., Chambers, P. et al. (6 more authors) (2025) Corrigendum to “Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly(ADP-ribose) polymerase inhibitor treatment for advanced-stage ovarian cancer: A retrospective cohort study” [Eur J Cancer 222 (2025) 115472]. European Journal of Cancer, 223. 115492. ISSN 0959-8049

Steventon, L., Nicum, S., Chambers, P. et al. (6 more authors) (2025) Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly(ADP-ribose) polymerase inhibitor treatment for advanced-stage recurrent ovarian cancer: A retrospective cohort study in England. European Journal of Cancer, 222. 115472. ISSN 0959-8049

Steventon, L., Nicum, S., Man, K. et al. (6 more authors) (2025) Time to adjuvant chemotherapy and overall survival in advanced-stage ovarian cancer patients in England: a population-based retrospective cohort study. ESMO Real World Data and Digital Oncology, 8. 100143. ISSN 2949-8201

Probert, J., Dodwell, D., Broggio, J. et al. (4 more authors) (2025) Identification of recurrences in women diagnosed with early invasive breast cancer using routinely collected data in England. BJC Reports, 3. 39. ISSN 2731-9377

Elder, K., Coles, C., Dodwell, D. et al. (23 more authors) (2025) SMALL: open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer—protocol for a phase III randomised multicentre trial. BMJ Open, 15 (4). e099702. ISSN 2044-6055

Goyal, A., Mann, G.B., Fallowfield, L. et al. (28 more authors) (2021) POSNOC—POsitive Sentinel NOde : adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy : a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes. BMJ Open, 11 (12). e054365.

Coleman, R.E., Collinson, M., Gregory, W. et al. (20 more authors) (2018) Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). JOURNAL OF BONE ONCOLOGY, 13. pp. 123-135. ISSN 2212-1374

Wilson, C., Hinsley, S., Marshall, H. et al. (4 more authors) (2017) Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer – An AZURE (BIG 01/04) sub-study. Journal of Bone Oncology, 9. pp. 48-54. ISSN 2212-1374

Lester, J.E., Dodwell, D., Brown, J.E. et al. (6 more authors) (2012) Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial. Journal of Bone Oncology, 1 (2). pp. 57-62. ISSN 2212-1374

Coleman, R. orcid.org/0000-0002-4275-1043, Woodward, E., Brown, J. et al. (11 more authors) (2011) Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment, 127 (2). pp. 429-438. ISSN 0167-6806

Coleman, R.E. orcid.org/0000-0002-4275-1043, Winter, M.C., Cameron, D. et al. (11 more authors) (2010) The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. British Journal of Cancer, 102 (7). pp. 1099-1105. ISSN 0007-0920

Lester, J.E., Dodwell, D., Horsman, J.M. orcid.org/0000-0002-6454-642X et al. (2 more authors) (2006) Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom. British Journal of Cancer, 94 (1). pp. 30-35. ISSN 0007-0920